NRX Pharmaceuticals

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NRx Pharmaceuticals reports strong Q1 performance and growth opportunities

NRx Pharmaceuticals made strides in innovation, debt reduction, and financial stability in Q1 2024.
The company's focus on mental health treatments and addressing unmet medical needs shows market relevance.
Challenges include resolving short interest concerns and securing FDA approvals for key drugs.
Opportunities lie in out-licensing, revenue generation, and partnerships for growth and market expansion.

NRx Pharmaceuticals reports progress in financials and scientific breakthroughs

NRx Pharmaceuticals showcased financial and scientific progress, positioning itself for growth and market penetration.
Strategic initiatives like clinic roll-up and commercial targeting demonstrate a proactive approach to market challenges.
While facing transitions and competition, NRx Pharmaceuticals has opportunities for expansion and innovation in psychiatric treatments.
The company's focus on financial stability, product development, and market strategies reflects a comprehensive growth strategy.

NRx Pharmaceuticals reports improved financials and plans for growth

NRx Pharmaceuticals demonstrated improved financial performance and strategic planning in Q3 2024, with reduced losses and enhanced operational efficiency.
The company's focus on innovation, acquisitions, and precision psychiatry clinics highlights a commitment to growth and market leadership.
While facing challenges in revenue recognition and clinic valuations, NRx Pharmaceuticals has opportunities to drive revenue growth and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RADNOR, Pa. , Nov. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its third quarter 2023 financial results after the market closes on Tuesday, November 14, 2023, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases.

NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023

No current FDA-approved formulation of ketamine for treatment of depression and suicidality Partners are developing a proprietary, tamper and diversion-resistant formulation and packaging Finished drug with two-year shelf stability targeted for November 2024, pending FDA approval Partners aim to submit New Drug Application by March 1, 2024 RADNOR, Pa. and WEST COLUMBIA, S.C.

NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression

FDA-compliant manufacture of intravenous Ketamine is a required component of a New Drug Application Intravenous Ketamine has become widely used for treating depression and suicidality but has never been presented to FDA for approval Potential to file New Drug Application for Ketamine in 2024 based on existing clinical data and newly-developed, modern commercial manufacturing protocols Further information is anticipated to be released in an upcoming 8K securities filing RADNOR, Pa. , Oct. 31, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced the signing of a development contract to manufacture a presentation of ketamine suitable for intravenous administration under current FDA manufacturing regulations.

NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression

"Study May Proceed" letter received from FDA IND preclinical requirements are consistent with studies already in progress to support treatment of Bipolar Depression Potential to initiate registrational studies in 2024, pending receipt of data from already-completed DOD-funded trial of D-cycloserine RADNOR, Pa. , Oct. 26, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced further alignment with the FDA Division of Anesthesiology, Addiction Medicine, and Pain Medicine in connection with the development of NRX-101 for treatment of Chronic Pain.

NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

Previously announced data sharing agreement for intravenous ketamine Newly available data highlight the need for a labeled form of IV ketamine that can qualify for insurance reimbursement Need for intravenous ketamine is heightened by recent failure of intranasal ketamine to treat suicidality. Currently approved esketamine is not available for patients with bipolar depression The importance of appropriately labeled intravenous ketamine is highlighted by recent FDA warning letter and prior warning letters against compounding and off-label uses of ketamine for psychiatric care JUPITER, Fla.

NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor Conference

RADNOR, Pa. , Oct. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the 8th Annual Dawson James Conference on Thursday, October 12th, 2023, at the Wyndam Grand Jupiter at Harbourside Place, in Jupiter Florida.

NRx Pharmaceuticals to Present at 8th Annual Dawson James Conference

NRx Pharma (NRXP) receives FDA clearance to begin clinical development for its lead candidate, NRX-101, to treat chronic pain.

NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up

Allows initiation of the NRX-101 commercial development to treat Chronic Pain Company plans to seek Fast Track and Breakthrough Therapy Designations from FDA while awaiting near-term results of Dept of Defense-funded trial RADNOR, Pa. , Oct. 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that FDA has given the company clearance to proceed with human trials to treat Chronic Pain under the Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA) for the use of NRX-101.

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

Focus on implications of the recent Data Sharing Agreement relating to a landmark trial of Ketamine in the treatment of Suicidal Depression NMDA antagonist highly effective in Bipolar subgroup (p

NRx Pharmaceuticals Publishes Shareholder Update Letter

RADNOR, Pa. , Sept. 18, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D.

NRx Pharmaceuticals to Present at the Sidoti Virtual Small Cap Conference

Ketamine, an NMDA blocker, was highly effective in Bipolar subgroup (p

NRX Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Bipolar Depression

Industry veteran Richard Narido joins the NRx Pharmaceuticals management team RADNOR, Pa. , Sept. 14, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has entered into an agreement (the "Agreement") with LS Associates, a division of LifeSci Advisors, LLC ("LSA"), pursuant to which LSA will provide certain consulting services to the Company, including but not limited to, arranging for the provision of the Company's Interim Chief Financial Officer.

NRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and Support

RADNOR, Pa. , Sept. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D.

NRx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NRX-101 demonstrated potent antibacterial effect against antibiotic-resistant pathogens in culture medium and in an artificial urine model D-cycloserine (DCS), a key component of NRX-101, was originally developed as an anti-infective in the 1950's but was replaced by antibiotics that have since lost effectiveness against complicated Urinary Tract Infections (cUTI) In an era when 90% of cUTI pathogens demonstrate resistance to standard antibiotics, NRX-101 may prove effective in treating cUTI and preventing urosepsis RADNOR, Pa. , Sept. 6, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced new data that demonstrate potent in vitro activity of NRX-101 (D-cycloserine + lurasidone) against reference strains of Urinary Tract pathogens known to cause complicated urinary tract infections (cUTIs).

NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens

IND builds on previously-published, preliminary evidence of efficacy Filing is supported by robust manufacturing, pre-clinical and clinical data already reviewed by FDA for NRX-101 associated with treatment of bipolar depression RADNOR, Pa. , Aug. 30, 2023 /PRNewswire/ - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced submission an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of NRX-101 to treat Chronic Pain.

NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain

NRx Pharmaceuticals received approximately $1.2 million in cash from existing investors Preferred shares to sold at $0.40; shares convert to one common share and one common warrant ($0.40/ strike) after six months Share purchase will assist the Company in development of NRX-101 in Suicidal Bipolar Depression and Chronic Pain and general corporate purposes RADNOR, Pa. , Aug. 29, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it entered into a definitive purchase agreement subject to standard closing conditions with accredited investors to purchase 3,000,000 shares of preferred stock at $0.40 per share, which will convert, after six (6) months into 3,000,000 common shares and 3,000,000 warrants to purchase common stock at a purchase price of $0.40 per share; the term on these warrants is five (5) years.

NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share

Big Rock Partners

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (“NRx”) on behalf of the company's long-term shareholders. NRx is a clinical-stage pharmaceutical company. The current company was formed in May 2021 via a business combination with SPAC entity Big Rock Partners Acquisition Corp. (NASDAQ: BRPA), with NRx as the surviving, publicly traded entity. Immediately following the closing of the SPAC transaction, shares of NRx traded.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Investors to Contact the Firm

NRX Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Steve Willard - CEO & Director Jonathan Javitt - Chief Scientist & Director Seth Voorhees - CFO Conference Call Participants Ed Woo - Ascendiant Capital Markets Operator Good day and welcome to the NRX Pharmaceuticals Incorporated Second Quarter 2023 Earnings Conference Call. [Operator Instructions].

NRX Pharmaceuticals, Inc. (NRXP) Q2 2023 Earnings Call Transcript

Two near-term data catalysts expected in 2023 Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and commercialization of NRX-101 in suicidal bipolar depression; potential for up to $330 million in milestones and double-digit royalties Publication of STABIL-B trial in the International Journal of Bipolar Disorders: first oral antidepressant to demonstrate reduction in suicidality with significant improvement in depression scores compared to standard of care medication Ongoing Phase 2b/3 trial of NRX-101 in suicidal bipolar depression is within 20 patients of data readout. Data expected in Q4 2023 Newly released data demonstrate high levels of compliance and inter-rater reliability Licensed US Patent for use of D-Cycloserine (DCS) to treat chronic pain Announced plan to develop NRX-101™   for chronic pain indications, awaiting results of 200 person DOD-funded trial in treatment of chronic pain with DCS in coming months Filing Investigational New Drug application with FDA to treat chronic pain with NRX-101 Management to host a conference call today at 4:30 PM ET RADNOR, Pa.

NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

RADNOR, Pa. , Aug. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its second quarter 2023 financial results after the market closes on Monday, August 14, 2023, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.

NRx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 14, 2023

NRx has Licensed US Patent 8,653,120 for use of D-Cycloserine to treat Chronic Pain Dr. Vania Apkarian, a world leader in pain and D-Cycloserine (DCS) research, has joined the NRx Scientific Advisory Board RADNOR, Pa. , Aug. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it has made key advances in developing NRX-101 to treat Chronic Pain.

NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain

NEW YORK , June 27, 2023 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased NRx Pharmaceuticals Inc. (f/k/a Big Rock Partners Acquisition Corp.) ("NRXP" or the "Company") (NASDAQ: NRXP) stock prior to May 24, 2021 and still hold such stock. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of NRXP's 2021 de-SPAC merger.

NRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

RADNOR, Pa. , June 20, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard, J.D.

NRx Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

PHILADELPHIA , June 15, 2023 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx") on behalf of the company's long-term shareholders. NRx is a clinical-stage pharmaceutical company.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Shareholders to Contact the Firm

RADNOR, Pa. , June 9, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 9,670,002 shares of common stock at a purchase price of $0.65 per share of common stock.

News for NRX Pharmaceuticals Stock (NRXP)